Macrogenics Inc (NAS:MGNX)
$ 4.36 0.25 (6.07%) Market Cap: 273.08 Mil Enterprise Value: 107.83 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 60/100

MacroGenics Inc to Review Flotetuzumab Data Presented at the ASH Annual Meeting - Call Transcript

Dec 10, 2019 / 01:00AM GMT
Release Date Price: $9.33 (-5.09%)
Operator

Good evening. We will begin the MacroGenics 2019 AHS (sic) [ASH] conference call in just a moment. (Operator Instructions) At this point, I will turn the call over to Anna Krassowska, Vice President, Investor Relations and Corporate Communications of MacroGenics.

Anna Krassowska
MacroGenics, Inc. - VP of IR & Corporate Communications

Thank you. Good evening, and welcome to the MacroGenics conference call to review the flotetuzumab data presented at the American Society of Hematology Annual Meeting here in Orlando, and to discuss clinical development plans for the program. The presentation that accompanies this conference call is available under the Investors tab on our website at macrogenics.com. You can also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately 2 hours after the call is completed.

Before we begin, I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans and prospects that constitute forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot